Loading stock data…
Opko Health, Inc. (OPK)
$1.59-0.05 (-3.05%)
Market ClosedLast close Sep 8
OPKO Health, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
OPKO Health, Inc. in the Healthcare sector is trading at $1.59 with a market capitalization of $1.0B. Wall Street consensus targets $4.38 (4 analysts), implying a +175.2% move over the next 12 months. The stock is currently near its 52-week high of $1.73, remaining 22.3% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +175.2% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $163.58M↑ | $124.20M↓ | $148.45M↓ | $151.67M↓ | $156.81M |
| Gross Profit | $80.02M↑ | $45.76M↓ | $64.03M↑ | $49.89M↑ | $49.40M |
| Operating Income | -$25.04M↑ | -$51.02M↓ | -$38.32M↑ | -$53.52M↑ | -$59.98M |
| Net Income | -$8.42M↑ | -$54.85M↓ | -$31.26M↓ | $21.63M↑ | -$148.44M |
Peer Comparison
JNJUNHPFE
Fundamentals
OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates in two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment develops MDX2001, a...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.04B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.49
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-6.16%
Volume
Today's trading volume
2.57M
Recent News
Cocrystal Pharma: The Strategic Reset Investors May Be Missing
By Mike Sheikh Cocrystal Pharma (NASDAQ: COCP) may look like another undercapitalized, clinical-stage biotech searching for its niche, and in need of a rescue, but there is more to this story than what meets the eye. Investors glancing at the stock chart may miss the signs of a strategic reset orchestrated by biotech legends, and miss […] The post Cocrystal Pharma: The Strategic Reset Investors May Be Missing appeared first on ExecEdge.
Why Is OPKO Health (OPK) Down 9.7% Since Last Earnings Report?
OPKO Health (OPK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain OPK Stock in Your Portfolio for Now
OPKO Health's growth outlook is supported by RAYALDEE, strategic partnerships, BioReference restructuring and multiple pipeline catalysts.
OPK Raises $125 Million Against Royalties: What Investors Should Know
OPKO Health secured $125 million in royalty-backed financing, adding non-dilutive capital while retaining long-term exposure to mazdutide growth in China.
Is OPK Worth Buying as Valuation Meets Improving Business Trends?
OPKO Health pairs a discounted forward sales multiple with narrowing losses and partnership support, but early-stage clinical risk keeps the investment case balanced.